Fluvastatin is a potent synthetic competitive inhibitor of /3-hydroxy-/?-methyl-glutaryl-coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme in the biosynthetic pathway for hepatic cholesterol synthesis. The therapeutic indication is reduction of elevated total and low-density lipoprotein cholesterol levels. Results from four toxicity studies in beagle dogs and one study in rhesus monkeys following oral administration of fluvastatin are reported. In two 26-week dog studies, doses were 0, 1, 8, or 48 mg/kg/day (reduced to 36 mg/kg/day in Week 7) and 0, 6, 24, or 36 mg/kg/ day (reduced to 30 mg/kg/day in Week 2). In a 2-year dog study, doses were 0, 1, 8, or 16 mg/kg/day. Dose levels in the 26-week monkey study were 0, 0.6, 12, and 48 mg/kg/day (raised to 84 mg/ kg/day in Week 17 and to 108 mg/kg/day in Week 22). In these studies, evaluations included clinical and physical examinations, body weight and food consumption, electrocardiography, ophthalmoscopy, hematology and clinical chemistries, urinalysis, blood drug concentration, and macroscopic and microscopic examinations of observed lesions and representative tissues. In the 26-and 52-week dog studies and the monkey study, lenticular biochemistry, the HMG-CoA reductase activity of liver microsomes, and serum lipid concentrations were investigated. The fourth dog study was a single-dose toxicokinetic study in which 48 mg/kg [ J H]-fluvastatin was monitored for up to 2 weeks. Sampling was limited to ocular tissues for enzyme analysis. Doses of 3=24 mg/kg/day were lethal in dogs. At lethal doses, ataxia, convulsions, fecal blood, mulrifocal congestion and hemorrhage, isolated foci of malac ia in the medulla oblongata, and liver necrosis were observed. Reduced weight gain, emesis, cataracts, elevated liver enzymes, reduced cholesterol, and gallbladder inflammation with mucosal hyperplasia occurred at 3=8 mg/kg/day. In contrast to other HMGCoA reductase inhibitors, fluvastatin did not cause significant central nervous system hemorrhage or testicular changes in dogs. Monkeys tolerated exposure to fluvastatin well with only mild gallbladder changes observed. Reduced serum cholesterol and slight hyperplasia of the gallbladder mucosa occurred in the 12 and 48/84/108 mg/kg/day groups, c i»6 soday of To
Fluvastatin
([R*,S*-(E)]-(±)-7-[3-(4-fluorophenyl)-l-(1 -methylethy])-1 H-indol-2-yl)]-3, 5-dihydroxy-6-heptenoicacid sodium salt) (Fig. 1 ) is a potent, competitive inhibitor of /?-hydroxy-/?-methyl-glutaryl-coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme in the cholesterol biosynthetic pathway in the liver (Engstrom et at, 1988; Kathawala, 1991) . This drug is a mevalono-lactone derivative. Its pharmacological profile is similar to compactin, lovastatin, pravastatin, and simvistatin ( Fig. 1 ). Unlike these earlier inhibitors of HMG-CoA reductase, which are fungal metabolites or derivatives, fluvastatin, also known as XU 62-320, is entirely synthetic and is not a prodrug. The primary human therapeutic indication for fluvastatin is the treatment of elevated total and low-density lipoprotein cholesterol levels in patients with hypercholesterolemia (Levy et ai, 1993) . The potential for long-term therapy in man necessitated extensive nonclinical investigations in laboratory animals. This paper presents the results from four toxicity studies in beagle dogs and one in rhesus monkeys. The purpose of these studies was to provide data related to the administration of fluvastatin for comparison with results reported from preclinical studies of other HMG-CoA reductase inhibitors (Berry et ai, 1988; Gerson et ai, 1991) .
In dog studies, one fungal derivative, lovastatin, induced neurotoxicity in which a hemorrhagic encephalopathy related to endothelial degeneration occurred in the optic nerve. It was seen at the lethal dose level which was 180 times the human dose. While evidence of axonal degeneration was seen at a level 60 times the intended human dose of lovastatin, no adverse effects were seen in the CNS at 30 times the human dose for 2 years (Berry et ai, 1988) . Another manifestation of toxicity sometimes seen with this pharmacological class of substances is the development of lenticular opacities in the areas of anterior lenticular cell growth and differentiation (Gerson et ai, 1990) . Reported frequencies of cataract development varied with dose and compound. Also noted were transient elevations of serum enzymes, an irregular frequency of testicular degeneration (MacDonald et ai, 1988) , and hypertrophy and hyperplasia of the gallbladder mucosa. 0272-0590/96 $12.00 Copyright O 1996 by the Society of Toxicology All rights of reproduction in any form reserved. 
METHODS

Antemortem Evaluations
Young adult purebred Beagle dogs (approximately 8 to 9 months old) were obtained from White Eagle Laboratories (Doylestown, PA). The animals were kept in stainless steel cages in air-conditioned rooms and fed a daily ration of 350 g of Purina Certified Dog Chow. Water was available ad libitum.
For all 26-week studies, clinical observations and measurements of food consumption were recorded daily; body weights weekly; and physical examinations, electrocardiograms, hematologic, clinical chemistry, and urinalysis evaluation periodically at approximately 3-to 4-week intervals. Pretest observations and measurements were collected at Weeks -1 and -4. For the 2-year study, the same parameters were also evaluated periodically, but at longer intervals.
The first 26-week toxicity study (Study A) consisted of four groups of dogs (six males and six females per group) weighing 6 to 14 kg. Fluvastatin was administered orally using gelatin capsules at dose levels of 0, 1, 8, or 48 mg/kg/day (reduced to 36 mg/kg/day in Week 7). An interim sacrifice of three males and three females per group occurred in Week 5. Indirect ophthalmoscopic and photo slit-lamp examinations were performed on all animals in Pretest 8, 12, 18, 24, and 27 . Surviving animals at terminal sacrifice had the left lens and aqueous humor removed at necropsy and analyzed biochemically. To assess the pharmacologic efficacy of fluvastatin in the dog, additional blood samples were collected in Drug Weeks 8, 18, and 26. Total serum cholesterol and triglyceride levels were analyzed. Cholesterol levels in HDL and VLDL + LDL (high-density lipoprotein) fractions of the serum were also determined. Liver microsomal HMG-CoA reductase activity was measured in terminal sacrifice animals (Week 27). Blood samples were collected immediately before dosing and at 0.5, 1, 2, 4, 6, 8, and 24 hr postdosing on Drug Day I and in Drug Weeks 3 and 25. In Drug Weeks 7 and 17, blood samples were drawn only at 2 hr (Cm.,) and 24 hr (C^) postdrug administration. Blood concentrations of unchanged fluvastatin were determined by highpressure liquid chromatography with fluorescence detection (Tse et al., 1990) .
The goals of the second 26-week study (Study B) were to establish a no-toxic-effect level (NTEL) and threshold level of cataract induction by fluvastatin It consisted of four groups (three males and three females per group) weighing 7 to 15 kg. Fluvastatin was administered orally in gelatin capsules at the following dose levels: 0, 16, 24, or 36 mg/kg/day (reduced to 30 mg/kg/day in Week 2). Indirect ophthalmoscopic and photo slit-lamp examinations were done in Pretest 8, 10, 15, 17, 19, 22, and 26 . Surviving animals at terminal sacrifice had the left lens and aqueous humor removed at necropsy and analyzed biochemically. In addition, serum was collected to assess phannacologic efficacy of fluvastatin on total cholesterol, triglycerides and HDL, and VLDL + LDL cholesterol. Liver microsomal HMG-CoA reductase activity was measured in all terminal sacrifice animals in Drug Week 27. Fluvastatin concentrations in blood were determined in Drug Weeks 1 (Drug Day 1), 2, 10, 15, 19, and 24. Blood samples were collected before dosing and at 0.5, 1, 2, 4, 6, 8, and 24 hr postdosing in Drug Weeks 1, 2, 10, and 24, and at 2 and 24 hr postadministration in Drug Weeks 15 and 19.
The 2-year dog toxicity study (Study C) consisted of four groups (four males and four females per group) weighing 3 to 6 kg. Fluvastatin was given orally in gelatin capsules at dose levels of 0, 1, 8, or 16 mg/kg/day. Indirect ophthalmoscopic and photo slit-lamp examinations were done in Pretest 9, 12, 18, 26, 38, 52, 65, 77, 92, and 104 . At terminal sacrifice the left lens and aqueous humor were removed at necropsy and analyzed biochemically. Blood levels of fluvastatin were determined in Drug Weeks 1, 15, 30, 43, 51, 64, 76, 91 , and 103 in samples obtained 0.5, 1, 2, 4, 6, 8, and 24 hr postdosing. All animals were sacrificed in Week 105.
A 26-week study was done in rhesus monkeys to determine the potential of fluvastatin to induce cataracts. It consisted of four groups each containing six males and six females. They were approximately 2 years old and weighed between 7 and 20 kg. The animals were kept in individual stainless steel metabolism cages in an air-conditioned room. Each animal received Purina Certified Primate Chow and water ad libitum. They were divided into four groups containing three males and three females each. In addition, one male and one female were included in the control group and two additional males and females in the high-dose group for a 13-week interim sacrifice. Fluvastatin was administered orally by esophageal intubation of gelatin capsules at dose levels of 0, 0.6, 12, or 48 mg/kg/day. The 48 mg/ kg/day dose level was escalated to 84 mg/kg/day at Week 17 and to 108 mg/kg/day at Week 22.
Indirect ophthalmoscopic and photo slit-lamp examinations were done in Pretest 8, 12, 18, and 26 . Monkeys surviving to termination of the study in Drug Week 27 had the left lens removed, weighed, and analyzed biochemically at necropsy. Serum was evaluated for pharmacologic efficacy of fluvastatin on levels of total cholesterol, triglycerides and HDL, and VLDL + LDL cholesterol. Liver microsomal HMG-CoA reductase activity and liver lipids (triglycerides and cholesterol) were measured in all animals at the terminal sacrifice in Drug Week 27. Fluvastatin drug concentrations in blood were determined in all monkeys in Drug Weeks 1 (Drug Day 1), 3, 7, 11, 19, and 25 . Blood samples were collected immediately before dosing and at 0.5, I, 2, 4, 6, 8, and 24 hr postdose in Drug Weeks 1,2, 11, and 25, but only at 2 and 24 hr postdrug administration in Drug Weeks 7 and 19.
Biochemical evaluations.
Lipoproteins were separated by ultracentnfugation (Davies, 1964) . Cholesterol levels were measured enzymatically in the whole serum and fractions (Leon et ai, 1976) . Liver lipids were extracted and analyzed for triglycerides and cholesterol (Folch et ai, 1957) . HMG-CoA reductase activity was measured using microsomal suspensions prepared from fresh liver homogenates frozen at -70°C until assayed (Ackerman et al., 1977) .
Toxicokinetic evaluations.
In the toxicokinetic study (Study D), groups of one male and one female dog each were given a single dose of 48 mg/ kg [ 3 H]fluvastatin (0.69 /iCi/mg). They were humanely sacrificed at various intervals between I and 336 hr postdose. Blood levels of unchanged drug and total radioactivity were measured I hr after dosing and before sacrifice. Total radioactivity was determined in the aqueous humor and lens segments.
Postmortem evaluations.
With the exception of the toxicokinetic study animals, all animals were sacrificed by exsanguination during deep barbiturate anesthesia. Most tissues were preserved by immersion in 10% neutral buffered formalin. Testes were preserved in Bouin's solution and the right eye and lens in glutaraldehyde. The left lens and aqueous humor were collected and weighed for histochemical analysis. The left globe was preserved in glutaraldehyde for microscopic evaluation.
Complete macroscopic examinations were performed on all animals. Specimens were collected from all macroscopic lesions and representative samples of all tissues. They were preserved in 10% neutral buffered formalin or other appropriate fixatives, embedded in paraffin, and stained with hematoxylin and eosin (H&E) for microscopic examination. Occasionally, special stains were performed on selected tissues. The organs weighed at terminal sacrifice included the brain, liver, kidneys, adrenals, pituitary, and gonads. In previous studies, fluvastatin was found to induce gastnc forestomach hyperkeratosis and hyperplasia in rats and mice as a function of dose and time (Robison et ai, 1994) . Therefore, multiple specimens of the stomach, including the cardiac region, and the esophagus of the dog and rhesus monkey were examined.
Location of visible lenticular abnormalities in the lenses was recorded. After freezing on dry ice, the left lens was separated into an equatorial ring and central cylinder, the central portion was then separated into anterior and posterior halves. The three lens parts were weighed separately and stored in plastic vials on dry ice. They were analyzed histochemically at the University of Bonn, Germany.
1 The biochemical examinations included water-soluble protein in the equatorial ring and inner central cylinder, measurements of aldose reductase, glutathione peroxidase, fructose-1,6-diphosphate aldolase, and phosphofructokinase in the equatorial ring and central cylinder, and glucose-6-phosphate dehydrogenase in the equator Concentrations of glutathione (oxidized and reduced), ATP, ADP, AMP, glucose, glucose 6-phosphate, fructose 6-phosphate, fructose, and sorbitol were measured in the lens inner cylinder. Protein profiles of the lens parts and aqueous humor were determined by isoelectric focusing. Linear regression was used for statistical analysis.
Other HMG-CoA reductase inhibitors have been shown to induce vascular damage and hemorrhage with related malacia in the central nervous system and optic nerve in dogs (Berry et ai. 1988) . Thus, in addition to histologic sections of medulla and spinal cord, the central nervous system was evaluated microscopically using three full coronal sections of brain including the brain stem. Three vertical semisenal sections were also prepared from each eye and available lens. One section included the optic nerve head.
RESULTS
Clinical and Postmortem Findings
Dog studies. In the first 26-week dog study (Study A), the dose level of 48/36 mg/kg/day was found to be lethal in the dog. Five of 12 animals died (Table 1 ). In the second 26-week study (Study B), 2 of 12 animals died in the 36/30 mg/kg/day group. No mortality occurred during the 2-year dog study.
In the 26-week and 2-year dog studies (Studies A, B, and C), the gallbladder and lens were target organs of toxicity. Cataracts were seen at and above dose levels of 16 mg/kg/ day and as early as Week 12 at 36/30 mg/kg/day (Tables 1  and 2 ).
Evidence of dose-dependent pharmacological activity was noted in each of the three studies. It was characterized by decreases in total serum cholesterol, triglycerides and cholesterol HDL, and VLDL + HDL lipoprotein fractions (Table 3 ). In the 26-week dog studies, elevations in hepatic microsomal HMG-CoA reductase activity occurred in treated animals ( 'Moribund animals. tically significant. In the initial 26-week study (Study A), the dose level of 48 mg/kg/day was reduced to 36 mg/kg/ day in Drug Week 7 after all surviving high-dose animals began exhibiting signs of ataxia, decreased locomotor activity, and depression. In some animals, blood was found in the feces. Of the 12 dogs in this group, 1 died on Day 157 and 4 were sacrificed in extremis on Days 12, 25, 26, or 43 (Table 1) . One moribund animal exhibited a single tonic convulsion and all decedents experienced ataxia and reduced locomotor activity before death. The animals that died or were sacrificed moribund had lost between 0.5 and 1.7 kg body wt. In the two dogs sacrificed in extremis on Days 25 and 26 of treatment (Study A) at the lethal dose level of 48/36 mg/ kg/day and in the three males from that group sacrificed in the Week 5 interim sacrifice, slight, focal, periaxonal vacuolization in the ventral portion of the reticular formation of the medulla oblongata was noted in both cross and longitudinal histologic sections (Table 5 ). Associated evidence of vascular injury or other central nervous system tissue damage was not observed. Following lowering the dose level from 48 to 36 mg/kg/day on Day 13, additional lesions of similar nature were encountered in the medulla oblongata of three of three high-dose animals examined from the 5-week interim sacrifice on Days 31 and 32. No additional evidence of nervous system tissue alterations was found in the four remaining members of this group or in the lower dose groups at termination of the 26-week treatment period for this study. No microscopic lesions of this type were observed in the nervous system in the second 26-week dog study (Study B) , in the subsequent 2-year study (Study C), or in the 26-week monkey study. Postmortem findings in dogs dying or sacrificed in extremis at the lethal dose of 48/36 mg/kg/day consisted of multifocal hemorrhage and congestion noted in the pancreas, liver, mesentery, mediastinum, intestines, diaphragm, and myocardium. Focal hepatic necrosis occurred in one animal and hydropic hepatocellular changes in two others. Triglycendes 32 ± 6 32 ± 9 25 ± 10 35 ± 15 39 ± 11 9 ± 3* 16 ± 5 8 ± 5* 9 ± 3* 10 ± 3* mg/dl 20 ± 5* 26 ± 8 24 ± 12 27 ± 7 33 ± 8 9 ± 3* 9 ± 2* 8 ± 3* 6 ± 2* 9 ± 6* 27 ± 6* 41 ± 10* 19 ± 10 22 ± 12 30 ± 13 8 ± 3* 8 ± 2* 28 ± 5* 39 ± 11* 3 ± 3* 10 ± 8* Transient emesis in the first 4 to 6 weeks was the only consistent clinical observation noted in the 26-week studies (Studies A and B). Emesis did not occur in the 2-year dog study. Emesis noted in animals of the mid-and high-dose groups during the first 4 weeks of the study was two to three times more frequent than in controls. Emesis was comparable thereafter.
Surviving dogs in the 48/36 mg/kg/day group had adequate body weight gain and presented no additional clinical signs. A statistically significant decrease in food consumption was recorded in the early (25%) and late phases (60%) of the study in the 48/36 mg/kg/day group (Table 1) . Bilateral cataracts had developed in most of the surviving 48/36 mg/ kg/day dogs by Week 12. In the 48/36 mg/kg/day group, total leukocytes were elevated approximately 100%. This was related to neutrophilia attributed to multiple hemorrhages and inflammation noted microscopically in several organs including the gastrointestinal tract (Table 5) . Statistically significant increases in alanine transaminase (ALT) and aspartate transaminase (AST) were found in the 48/36 mg/ kg/day dogs during most of the study. Alkaline phosphatase (AP) was statistically increased in that group at Week 26 (Table 2) . A dose-dependent statistically significant pharmacological decrease in total serum cholesterol (20 to 62%), HDL cholesterol (13 to 54%), and VLDL + LDL cholesterol (36 to 86%) was present at all dose levels. Similar decreases in serum triglycerides at the 8 and 48/36 mg/kg/day dose levels were also noted (Table 3) . A distinct, but not statistically significant, trend toward increased liver microsomal HMG-CoA reductase activity occurred in the treated dogs (Table 4) .
In Study B, the second 26-week dog study, one 36 mg/ kg/day dog died on Day 6, a second dog was sacrificed moribund on Day 12, and one 24 mg/kg/day dog died on Day 29. These deaths in two high-dose 36/30 mg/kg/day animals (Drug Days 6 and 12) and in one mid-dose 24 mg/ kg/day animal (Drug Day 29) were treatment induced. The deaths were related to the development of acute hemorrhage and inflammatory lesions occurring in the gallbladder and intestinal tract. No histologic alterations were detected in the central nervous system. As in Study A, the first 26-week dog study, the animals exhibited ataxia and decreased locomotor activity before death. Transient episodes of emesis were observed in all treated groups during Weeks 1 to 4 during the study. Drug-related decreases in body weight were observed in the three dogs that were found dead or sacrificed moribund. No other clinical signs were exhibited in survivors of that group. Occasional non-dose-dependent statistically significant increases in ALT, AST, and AP were noted in each of the treatment groups (Table 6 ). Statistically significant treatment-related decreases in serum cholesterol (25 to 63%), HDL cholesterol (27 to 45%), VLDL + LDL cholesterol (51 to 91 %), and elevated hepatic serum enzymes were present at dose levels 2=24 mg/kg/day (Table 3 ). An increase in HMG-CoA reductase activity in liver microsomes occurred (Table 4) . Bilateral cataracts were observed 113+111* in three 30 mg/kg/day dogs by Week 8 and in two 24 mg/ kg/day dogs by Week 13 (Tables 1 and 2 ). The 24 mg/kg/ day animal, which died on Day 29, had peak blood drug levels similar to animals from the 36/30 mg/kg/day group. In both 26-week studies (Studies A and B), the gallbladder was identified as a target organ of toxicity. In the mucosa, congestion, edema, hyperplasia, hypersecretion, and inflammation occurred at dose levels of 8 mg/kg/day and above (Tables 5 and 7 ). In contrast to the earlier two studies, the 2-year dog study (Study C) revealed no drug-related alterations in clinical findings, emesis, body weight, food consumption, or hematologic examinations. While evidence of an effect on the gallbladder was noted, it was nonprogressive. After 2 years of treatment with fluvastatin, only mild hypertrophy of the mucosa was observed at the 16 mg/kg/day level. Hyperplasia, cholecystitis, hemorrhage, or increased secretion was not present (Table 7) .
In Study C, the 2-year dog study, statistically significant elevations of the hepatic serum enzymes ALT and AST were noted in the 16 mg/kg/day group at Weeks 26 and 52 but were not elevated at Week 104. As in the 26-week studies (Studies A and B), levels of sorbitol dehydrogenase were not affected by treatment (Table 6 ). Statistically significant decreases in total cholesterol (21 to 50%), HDL cholesterol (13 to 40%), and VLDL + LDL cholesterol (57 to 75%) were noted (Table 3) . Triglycerides were decreased but not significantly. Bilateral lenticular opacities were seen in three 16 mg/kg/day dogs, the first appearing in Week 18 (Tables  1 and 2) .
In all three studies, blood drug concentrations revealed moderately rapid absorption with dose-dependent increases in AUCs (area under the concentration-time curve) up to 30 mg/kg/day. Above 30 mg/kg/day, the blood AUCs were overproportional to dose (Fig. 2) .
Cataractogenic activity was identified in the 2-year chronic dog study (Study C). The lowest cataractogenic effect level was 16 mg/kg/day and the NTEL was 8 mg/kg/ day in the 2-year study (Table 2) . Detailed biochemical analysis of the lens suggested changes consistent with accelerated aging (Evans et ai, 1988) . No biochemical changes were detected in the terminal sacrifice animals that were considered relevant to the lenticular opacities detected in either the second 26-week study or the 2-year study.
The radiolabel study in dogs (Study D) revealed the potential for fluvastatin to achieve and maintain significant drug levels in the lens. The highest levels were found in the equatorial ring and anterior cortex where new lens fiber development occurs (Fig. 3) .
Hepatotoxicity was not present at doses below 36 mg/kg/ day in the 26-week studies nor at any dose level in the 2-year study. No evidence of adverse effects was noted in the stomach or esophagus in any of the treated dogs.
Monkey Study
Four monkeys died or were sacrificed moribund during the study as a result of non-drug-related causes. No remarkable treatment-related lesions were noted in any of the dying animals. One mid-dose (12 mg/kg/day) animal died on Day 2 and one on Day 64. One high-dose (48/84/108 mg/kg/day) monkey died on Day 115 and one on Day 118. The deaths in one mid-dose and one high-dose animal were related to intubation errors, i.e., esophageal injury or perforation. The cause of death in the other two was not apparent. No evidence of treatment-related effects was noted during the thorough macroscopic and microscopic evaluations performed on these animals.
The only treatment-related histopathological change was trace to minimal epithelial hyperplasia of the gallbladder mucosa. It occurred in four of five 12 mg/kg/day animals at Week 26 and in three of four 48/84/108 mg/kg/day animals at Weeks 13 and 26. Throughout the 26-week monkey study there were no adverse clinical signs, ophthalmological changes, or effects on body weight gain or food intake that were considered related to treatment. One 48/84/108 mg/kg/ day female had moderate increases in ALT and AST in Week 26 of about three times baseline values. In the 12 and 48/84/104 mg/kg/day dose levels, the total serum cholesterol decreased approximately 15 to 18% below concurrent control values throughout the study. This decrease became greater (33 to 44% decrease) when the dose was increased to 104 mg/kg/day. The HDL cholesterol and VLDL + LDL cholesterol values decreased (not statistically significant) approximately 17 to 23% and 16 to 28%, respectively, in the 48/84/108 mg/kg/day dose group. Escalation to 108 mg/kg/ day resulted in a statistically significantly greater decrease (47%) compared to controls. Blood drug concentrations showed dose proportionality up to 48 mg/kg/day. Overproportionality was observed upon escalation from 48 to levels of 84 and 108 mg/kg/day. Liver lipid concentration and HMG-CoA reductase activity were not affected by treatment. In Week 13, two control and four 48/84/108 mg/kg/ day animals and, in Week 27, all surviving animals were necropsied and given thorough postmortem examinations. No increase in liver weight or histopathological evidence of hepatotoxicity was noted. Treatment-induced effects were not detected in the stomach or esophagus.
DISCUSSION
Fluvastatin is a potent inhibitor of hydroxymethylglutaryl-CoA reductase, HMGR, the rate-limiting enzyme in the biosynthetic pathway for cholesterol (Engstrom et at, 1988) . The studies reported herein revealed potent reductions in serum cholesterol in dogs and monkeys. In these studies, fluvastatin was shown to maintain potent dose-related reduc- tion in serum cholesterol levels in dogs treated for up to 2 years and in monkeys treated for 26 weeks. On a percentage basis, cholesterol was reduced more in the VLDL + LDL lipoprotein fraction dian in the HDL fraction, but quantitatively the greater reduction was with HDL. The more atherogenic LDL fraction was reduced most, up to a maximum reduction of 95%. There was also an improvement in the atherogenic index (HDL:total cholesterol ratio). Potent doserelated reduction in serum triglycerides was observed in 26-week dog studies, but the effect was diminished in the 2-year study. In monkeys, fluvastatin was less active than in rats or dogs. In the high dose of 48 mg/kg it did reduce cholesterol levels moderately in monkeys beginning at 4 weeks of treatment and continuing through the 26th week. Serum triglycerides were reduced in monkeys by fluvastatin treatment throughout the study. Due to variability, this was not statistically significant. The absence of change or slight increase in hepatic HMGCoA reductase activity in liver microsomes prepared from animals treated with fluvastatin is consistent with data in rats. When HMG-CoA reductase is inhibited and plasma LDL cholesterol is lowered, the liver synthesizes more enzyme in an attempt to compensate for the reduced liver cholesterol pools. The newly synthesized enzyme is inactivated in vivo by fluvastatin as indicated by the continuing inhibition of plasma cholesterol levels. During preparation of the microsomes, the inhibitory agent (fluvastatin) is washed out of the microsomes and the newly synthesized HMG-CoA reductase pool can be measured as active enzyme.
These results are consistent with the findings in dogs treated with lovastatin (Kovanen et ai, 1981) . In those studies, the inhibition of HMGR results in lowered synthesis of cholesterol and of LDL. In response, the liver increases LDL binding by increasing LDL receptor synthesis and, in addition, increases the LDL fractional catabolic rate. It appears that the mechanism by which the HMG-CoA reductase inhibitors, including fluvastatin, reduce serum cholesterol is through the increase in LDL removal.
In dogs treated with fluvastatin, the gallbladder developed congestion, edema, hyperplasia, hypersecretion, and inflammation of the mucosa at dose levels of >8 mg/kg/day. Similar changes have been noted with other HMG-CoA reductase inhibitors (Gerson et ai, 1991) . In monkeys, the gallbladder was also a target organ, but the changes were minor, consisting only of mild epithelial hyperplasia. In fact, the effects in monkeys were achieved only after escalation of the dose from 48 to 84 to 108 mg/kg/day. In addition, at toxic and/or lethal levels, hemorrhage and congestion of the gallbladder, as well as of the pancreas, liver, mesentery, mediastinum, intestines, diaphragm, and myocardium, occurred at lethal doses in dogs. Such changes were not detected in monkeys or in chronically treated dogs. Dogs (at 2516 mg/kg/day) and one monkey (48/84/108 mg/kg/day) showed some transient elevations of serum liver enzyme activities, although no liver pathology was seen in monkeys at dose levels up to 108 mg/kg/day. Liver pathology consisting of focal necrosis and hydropic changes occurred in some dogs only at lethal doses (48 mg/kg/day). Evidence of hepatotoxicity in dogs has been found with other members of this class of compounds (Gerson et ai, 1989; MacDonald et ai, 1988 H]fluvastatin and/or its metabolites continued to accumulate in the various lens fractions from 24 to 94 hr. These data indicate the potential for fluvastatin to accumulate in the lens upon multiple chronic administrations. some HMG-CoA inhibitors , but was not noted in dog studies with fluvastatin.
The occurrence of cataracts in the dog have been shown to be species specific and dose dependent. Rats (Robison et al, 1994 ) and monkeys did not exhibit cataract development at dose levels of fluvastatin that approximate a maximum tolerated dose in that species.
Cataracts were identified in the three chronic dog studies (Studies A, B, and C). The NOEL for cataracts was 8 mg/ kg/day. This dose is more than four times the recommended daily human dose. Cataracts in dogs can be considered a pharmacological class effect (Gerson et al., 1990; MacDonald et al, 1988) . Detailed biochemical analysis of the lens suggested changes consistent with aging, although no relevant biochemical changes were found in the lens in the 2-year study (Evans et al., 1990) . The lens fiber cell is rich in cholesterol and cholesterol synthesis has been reported in lens epithelial cells, particularly in subcapsular locations (Hitchener and Cenedella, 1985) . Radiolabel studies showed the potential for fluvastatin to achieve and maintain significant drug levels in the eye 1 to 5 days postdose with the highest levels found in the areas of new lens fiber development. Various other HMG-CoA reductase inhibitors which cause cataracts in dogs also have measurable drug levels in the lens (Gerson et al., 1990) . Although a causal relationship between serum cholesterol lowering and cataractogenesis has not been established, it has been suggested that high peak concentrations of inhibitors are more likely to be associated with cataract formation than chronic exposure. It is believed that agents achieving high plasma levels may produce high localized concentrations of inhibitor in the sensitive fiber cells eventually resulting in cataracts (Evans et al., 1988) .
Apart from the vacuolar changes found in the medulla oblongata in two of the five moribund animals sacrificed in extremis and three of the three males sacrificed during the 5-week interim sacrifice administered 48/36 mg/kg/day, no other findings were noted in the central nervous system of dogs in the 26-week studies.
When present in the animals dying or sacrificed moribund at the lethal dose level, the findings noted were not associated with any other CNS observations such as hemorrhage or vascular damage as reported with animals treated with other members of this pharmacological class. CNS lesions have been observed in dogs treated with all other members of this pharmacological class, i.e., lovastatin MacDonald et al, 1988) , simvastatin (MacDonald, 1991) , and pravastatin (Keim, 1990 ). The differences in CNS effects may be attributable to the permeability of the blood-brain barrier (BBB). Lovastatin and pravastatin readily cross the BBB (Berry et ai, 1988) , whereas fluvastatin passes into the brain only marginally (Guillot et ai, 1993) . Dogs receiving high dose levels of lovastatin exhibited neurologic signs (Berry et ai, 1988; MacDonald et ai, 1988) . Fluvastatintreated dogs did not exhibit significant neurological signs. Histopathological examination of the CNS of dogs treated with the other class members revealed a variety of changes that included edema, perivascular hemorrhages, vascular endothelial cell degeneration with perivascular malacia, degeneration of the centra] portions of the eighth cranial nerve, and axonal degeneration with neuronal chromatolysis in the optic system. In addition, some asymptomatic dogs demonstrated the optic system lesions. It was suggested that most lesions in the CNS were secondary to vascular effects, but a direct neurotoxic action was not excluded. A fluorinatedbiphenyl HMG-CoA reductase inhibitor (L-645,164) did not produce clinical signs in a 14-week study in dogs but induced extensive CNS lesions (Gerson et ai, 1991) . These lesions were described as spongiform degeneration of selected portions of the optic tracts in the CNS. They were apparently different from those caused by lovastatin on the basis of a lack of endothelial damage and focal hemorrhages. The authors indicated that the lesions were unique and may be related to its fluorinated biphenyl ring structure. However, the locations of the lesions in the CNS and their morphological descriptions suggest some similarity to the nonvascular lovastatin-induced lesions. Also, as fluvastatin has a fluorinated phenyl ring structure and does not cause comparable CNS lesions, the CNS lesions induced with L-645,164 may not be entirely attributed to this specific moiety. Dogs exhibited hepatic, lenticular, and gallbladder changes, viz. all of which can be considered pharmacological class effects. However, in contrast to other class members, dogs treated with fluvastatin did not develop comparable CNS or testicular changes. Dogs appear more sensitive than other species probably due to the fact that the degree of metabolism is less, resulting in higher systemic exposure (Tse et ai, 1990) to the parent drug. The gallbladder changes are considered related to direct chemical irritation which is exacerbated in the dog due to substantial biliary excretion of intact fluvastatin (Tse et ai, 1995) . In rodents, a direct contact irritation occurs in the nonglandular stomach following exposure to fluvastatin administered in the diet. Hyperplasia and hyperkeratosis of the squamous nonglandular gastric mucosa occur, whereas no similar changes have been found in the esophagus where direct contact with fluvastatin is transitory.
Monkeys tolerated exposure to fluvastatin extremely well. The anticipated pharmacological effects were detected only in the high dose. The only effects noted in tissues consisted of mild liver and gallbladder changes at high dose levels. No evidence of cataractogenesis was detected.
